HERO TEXT

CK-586

Cardiac myosin inhibitor

CK-4021586 (CK-586) is designed to be a novel, selective, oral, small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction (HFpEF). CK-586 was designed to selectively inhibit the ATPase of intact cardiac myosin but does not inhibit the ATPase of subfragment-1 of myosin (S1).

In preclinical models, CK-586 reduced cardiac hypercontractility by decreasing the number of active myosin cross-bridges during cardiac contraction thereby reducing the contractile force, without effect on calcium transients.

CK-586 was evaluated in a Phase 1 study assessing the safety, tolerability and pharmacokinetics of single and multiple oral doses of CK-586. CK-586 is now the subject of AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF), a Phase 2 clinical trial in a subgroup of patients with symptomatic HFpEF with hypercontractility and ventricular hypertrophy.

CK-586 is an investigational product and is not approved by any regulatory agency. Its safety and effectiveness have not been established.